New COVID-19 Vaccine Data;  Protection Gained by 3rd and 4th Doses

Translate to Spanish or other 102 languages!

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes
A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes

Mega Doctor News

- Advertisement -

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant.

To evaluate effectiveness of 2, 3, and 4 doses of mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) among adults with healthy immune systems, experts examined VISION Network data on more than 214,000 emergency department/urgent care visits and more than 58,000 hospitalizations with a COVID-19–like illness diagnosis in 10 U.S. states from mid-December 2021 through mid-June 2022. Study findings show:

  • When BA.1 was the predominant variant, vaccine effectiveness (VE) was 61% for two doses against COVID-19-associated hospitalizations; VE increased to between 85%–92% after receipt of a third/booster dose.
  • When BA.2/BA.2.12.1 became predominant, vaccine effectiveness with two doses was 24% against COVID-19-associated hospitalizations and increased to 52%–69% after a third/booster dose.
  • Patterns were similar for emergency department and urgent care encounters, with lower VE during BA.2/BA.2.12.1 predominance and higher VE with 3 or 4 doses compared to VE with 2 doses.
  • Among adults ages 50 years and older during BA.2/BA.2.12.1, vaccine effectiveness against COVID-19–associated hospitalization was 55% more than 4 months after a booster/third dose and increased to 80% more than a week after the fourth dose

COVID-19 vaccines remain our single most important tool to protect people against serious illness, hospitalization, and death. Getting vaccinated now will not prevent you from getting an authorized variant-specific vaccine in the fall or winter when they are recommended for you.  Given recent increases in deaths and hospitalizations associated with the BA.5 variant, everyone should stay up to date with recommended COVID-19 vaccinations, including additional booster doses for those who are moderately to severely immunocompromised and adults over 50.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Why Strength Training Is Your Best Defense Against Osteoporosis

Reports show women are at higher risk for developing the bone weakening condition as they get older.

Social Security Administration Corrects Millions of Records in Major Database Cleanup

The Social Security Administration (SSA) announced on October 20, 2026, that it has corrected millions of Social Security number records in what the agency describes as its most comprehensive record-integrity initiative in 91 years.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

A UTHealth Houston Physician Turned a Texas Teen’s Frightening Diagnosis into a Champion Title

Two years ago, Geordon Boulware, now 15, was at a routine dental visit in his hometown of Lufkin, Texas, when his dentist discovered he had an abnormal growth on his jaw. After meeting with a local oral surgeon, Geordon and his mom decided to seek treatment in Houston. 
- Advertisement -